HeartBeam (NASDAQ: BEAT) announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating its credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study, evaluating 184 patients, found that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison.
These results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. The company's technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians could identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. The full press release is available at https://ibn.fm/ainxV.
For more information about HeartBeam, visit https://www.heartbeam.com/indications for cleared indications for use. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
